INT137583

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 2006
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 2.62
Pain Relevance 1.75

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
arms 1
Ped (Mus musculus)
Pain Link Frequency Relevance Heat
Pain 64 99.16 Very High Very High Very High
Fibrositis 101 98.30 Very High Very High Very High
Inflammation 13 84.56 Quite High
cINOD 5 70.72 Quite High
Pain score 3 70.32 Quite High
epidural 1 55.04 Quite High
fibrosis 1 54.32 Quite High
Perioperative pain 1 53.12 Quite High
Kinase C 9 5.00 Very Low Very Low Very Low
Lasting pain 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Weight Loss 10 100.00 Very High Very High Very High
Pain 74 99.16 Very High Very High Very High
Fibromyalgia 101 98.30 Very High Very High Very High
Cardiovascular Disease 21 97.20 Very High Very High Very High
Metabolic Syndrome 53 85.32 High High
INFLAMMATION 14 84.56 Quite High
Body Weight Changes 3 79.44 Quite High
Fibrosis 1 54.32 Quite High
Post Operative Pain 1 53.12 Quite High
Hyperlipidemia 6 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Between February 2002 and August 2004, 71 patients with a mean age of 44 years (range : 24 to 73) underwent PED.
Positive_regulation (underwent) of PED
1) Confidence 0.40 Published 2006 Journal Acta Orthop Belg Section Abstract Doc Link 16889149 Disease Relevance 0.19 Pain Relevance 0.26
This observation could not be attributed to greater weight loss in the PED group, since the extent of weight loss was similar on both arms.
Neg (not) Positive_regulation (attributed) of PED in arms associated with weight loss
2) Confidence 0.19 Published 2008 Journal Nutr Metab (Lond) Section Body Doc Link PMC2588603 Disease Relevance 0.83 Pain Relevance 0.04
Milnacipran has proven to be effective in reducing FM pain.25,26,33–35 Compared with placebo, milnacipran was associated with significant improvements in PED and paper-based VAS pain measures.25,26 Significant sustained pain reductions were observed as early as 1 week after stable-dose treatment with milnacipran (P < 0.05 vs placebo), and maximal pain relief was reached by 9 weeks of treatment (Figure 2).25,26 The pain component of the composite responder analysis (ie, ?
Positive_regulation (improvements) of PED associated with pain and fibrositis
3) Confidence 0.04 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2877602 Disease Relevance 1.60 Pain Relevance 1.45

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox